Combining checkpoint inhibitors with oncolytic virotherapy can be a gamechanger

10 June 2019
Advances in the understanding of cancer immunotherapy and the development of multiple checkpoint inhibitors have dramatically changed the current landscape of cancer treatment. However, checkpoint inhibitors actually help only the minority of patients. Combining checkpoint inhibitors with oncolytic virotherapy can be a gamechanger. Multiple viruses are currently being tested in clinical trials in combination with anti-PD-1 or antiCTLA-4 antibodies, and thus far the results have been encouraging, particularly, response rate of combined therapy with checkpoint inhibitors (PD1) may exceed 60%. While the first finalized registration studies combining virus and Checkpoint inhibitors should be expected not faster than in 2022, RIGVIR is already successfully used by doctors, thus improving the efficacy of Checkpoint inhibitors not causing additional side effects. Please, be familiar with recent publication – case report about a 35‐year‐old male patient who was diagnosed with stage IIC skin melanoma that rapidly progressed after surgery. Treatment was continued with radiotherapy, which did not stop further spread of disease and the patient was put on a combination of nivolumab and Rigvir. Subsequently, the progression has slowed.
Read more:

Contacts for Media Inquiries

Rigvir Group
Address: 9-7 Teatra street, LV–1050, Riga, Latvia
Phone: +371 67 716 132